Close Menu

NEW YORK (GenomeWeb) – CRISPR/Cas9 gene editing firm Editas has filed a preliminary prospectus with US regulators for an initial public offering.

In its Form S-1, filed Monday with the US Securities and Exchange Commission, the Cambridge, Massachusetts-based company said that it plans to list on the Nasdaq Global Market under ticker symbol "EDIT."

The firm has not yet priced its shares or said how many shares it plans to offer. The IPO will be underwritten by Morgan Stanley, JP Morgan, Cowen and Company, and JMP Securities.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Matt Hancock, the UK health secretary, is calling for the swift rollout of predictive genetic tests, the Guardian reports.

A WHO panel is calling for a global registry of human germline gene-editing projects, according to Stat News.

Vox writes that lab mishaps involving pathogens are quite common.

In Genome Biology this week: analysis of wild and cultivated peach genomes, Hi-C-based pipeline for assembling microbial genomes from metagenomic data, and more.